BioInvent
Therapeutic antibodies developer implements a secured issue of shares worth SEK 160 million
Published in Health Business Week, November 18th, 2005
The share issue, which is secured to 100% by commitments from existing shareholders and new investors, will raise about SEK 160 million before issue expenses.
The main purpose of the offering is to finance the further development of the company's candidate drugs. The capital raised makes it possible to take several product candidates to the clinical phase.
In a short period the company has taken four product candidates from the preclinical research phase to the regulated development...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
Source: Health Business Week (2005-11-18)
More Articles from Health Business Week
- Bioniche Life Sciences, Inc.
Bladder cancer drug developer signs agreement for private financing - Biophan Technologies, Inc.
MRI-focused medical device maker reports net loss of $6M - Biotechnology Industry Organization
Biotech group supports Santorum/Hart bill to amend tax law - Business & Finance
Dionex Corp. notified it meets all Nasdaq listing requirements - C. R. Bard, Inc.
Single-patient-use medical products maker reports 5% increase in sales - Cell Therapeutics, Inc.
Xyotax developer appoints John Bauer to board of directors, chair of audit committee - More from this issue of Health Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
